Efocipegtrutide, a long-acting GLP-1/glucagon/gastric inhibitory polypeptide triple agonist, has shown promising efficacy and controllable toxicity in preclinical and Phase 1 studies for NASH. This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.